Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > Hey narmac
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(2261)
•••
Comment by Boomskidon Jan 25, 2023 8:40am
122 Views
Post# 35244619

RE:RE:RE:RE:Hey narmac

RE:RE:RE:RE:Hey narmacAll of that could be true, zwerp2000. But why did LT and The Placee want 75% of Biodexa? Why did they spend a year trying to make that happen? 

It wasn't Cresence's EGF. They were involved in that. They could have outbid Bioasis out of petty cash.

Was it Midatech that they wanted? Then why bring Bioasis into the deal? I suppose that bringing Bioasis in could be thought of in the context of LT and The Placee bringing value to Midatech and its shareholders in a benevolent takeover.

But I think it was most likely xB3 that was wanted. As a platform, xB3 could spawn opportunities that could be shared among all of the players, and I think that those xB3 opportunities were what LT and The Placee wanted most of all.

I think we should also want them. 

jd

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities